[go: up one dir, main page]

WO2010075424A3 - Compositions et procédés de réduction de gènes procaryotes - Google Patents

Compositions et procédés de réduction de gènes procaryotes Download PDF

Info

Publication number
WO2010075424A3
WO2010075424A3 PCT/US2009/069258 US2009069258W WO2010075424A3 WO 2010075424 A3 WO2010075424 A3 WO 2010075424A3 US 2009069258 W US2009069258 W US 2009069258W WO 2010075424 A3 WO2010075424 A3 WO 2010075424A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
prokaryotic genes
crispr
polynucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/069258
Other languages
English (en)
Other versions
WO2010075424A2 (fr
Inventor
Victor Kunin
Susan Yilmaz
Rotem Sorek
Philip Hugenholtz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO2010075424A2 publication Critical patent/WO2010075424A2/fr
Publication of WO2010075424A3 publication Critical patent/WO2010075424A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un polynucléotide isolé qui comprend une séquence d'acide nucléique à série CRISPR (clustered regularly interspaced short palindromic repeat) où au moins un espaceur de la CRISPR est suffisamment complémentaire d'une partie d'au moins un gène procaryote afin de réduire l'expression du gène procaryote. La présente invention concerne également des utilisations des polynucléotides et de compositions pharmaceutiques qui comprennent les polynucléotides.
PCT/US2009/069258 2008-12-22 2009-12-22 Compositions et procédés de réduction de gènes procaryotes Ceased WO2010075424A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19374208P 2008-12-22 2008-12-22
US61/193,742 2008-12-22

Publications (2)

Publication Number Publication Date
WO2010075424A2 WO2010075424A2 (fr) 2010-07-01
WO2010075424A3 true WO2010075424A3 (fr) 2010-09-02

Family

ID=42288422

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/069258 Ceased WO2010075424A2 (fr) 2008-12-22 2009-12-22 Compositions et procédés de réduction de gènes procaryotes

Country Status (1)

Country Link
WO (1) WO2010075424A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10660316B2 (en) 2016-11-04 2020-05-26 Akeagen, Inc. Genetically modified non-human animals and methods for producing heavy chain-only antibodies
US10765740B2 (en) 2016-06-05 2020-09-08 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US10920222B2 (en) 2018-04-30 2021-02-16 Snipr Biome Aps Treating and preventing microbial infections
US11147830B2 (en) 2015-05-06 2021-10-19 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US12076375B2 (en) 2022-06-29 2024-09-03 Snipr Biome Aps Treating and preventing E coli infections

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140113376A1 (en) * 2011-06-01 2014-04-24 Rotem Sorek Compositions and methods for downregulating prokaryotic genes
CA2853829C (fr) 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation et amelioration de la specificite de clivage des nucleases
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
EP2841572B1 (fr) 2012-04-27 2019-06-19 Duke University Correction génétique de gènes ayant subi une mutation
PE20190842A1 (es) 2012-05-25 2019-06-17 Emmanuelle Charpentier Arn de direccion a adn de dos moleculas
CN116622704A (zh) 2012-07-25 2023-08-22 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
KR102243092B1 (ko) 2012-12-06 2021-04-22 시그마-알드리치 컴퍼니., 엘엘씨 Crispr-기초된 유전체 변형과 조절
WO2014093479A1 (fr) * 2012-12-11 2014-06-19 Montana State University Contrôle de la régulation génétique guidé par arn crispr (répétitions palindromiques groupées, courtes régulièrement espacées )
EP2931892B1 (fr) 2012-12-12 2018-09-12 The Broad Institute, Inc. Procédés, modèles, systèmes et appareil pour identifier des séquences cibles pour les enzymes cas ou des systèmes crispr-cas pour des séquences cibles et transmettre les résultats associés
EP2931899A1 (fr) 2012-12-12 2015-10-21 The Broad Institute, Inc. Génomique fonctionnelle employant des systèmes crispr-cas, des compositions, des procédés, des banques d'inactivation et leurs applications
ES2658401T3 (es) 2012-12-12 2018-03-09 The Broad Institute, Inc. Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas
CN114634950A (zh) * 2012-12-12 2022-06-17 布罗德研究所有限公司 用于序列操纵的crispr-cas组分系统、方法以及组合物
WO2014113493A1 (fr) * 2013-01-16 2014-07-24 Emory University Complexes d'acide nucléique cas9 et leurs utilisations
CA2905432C (fr) 2013-03-14 2021-09-14 Caribou Biosciences, Inc. Compositions et procedes pour des acides nucleiques a ciblage d'acide nucleique
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
EP2999788B1 (fr) * 2013-05-22 2020-07-08 Northwestern University Clivage de l'adn orienté vers arn et édition génétique par l'enzyme cas9 provenant de neisseria meningitidis
SG10201710487VA (en) 2013-06-17 2018-01-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for Targeting Disorders and Diseases Using Viral Components
AU2014281027A1 (en) 2013-06-17 2016-01-28 Massachusetts Institute Of Technology Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation
ES2777217T3 (es) 2013-06-17 2020-08-04 Broad Inst Inc Suministro, modificación y optimización de sistemas de guía en tándem, métodos y composiciones para la manipulación de secuencias
WO2014204727A1 (fr) 2013-06-17 2014-12-24 The Broad Institute Inc. Génomique fonctionnelle utilisant des systèmes crispr-cas, procédés de composition, cribles et applications de ces derniers
EP3825406A1 (fr) 2013-06-17 2021-05-26 The Broad Institute Inc. Administration et utilisation de systèmes crispr-cas, vecteurs et compositions pour le ciblage et le traitement du foie
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
DK3041498T3 (da) 2013-09-05 2022-05-09 Massachusetts Inst Technology Afstemning af mikrobielle populationer med programmerbare nukleaser
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US20150098954A1 (en) * 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting
WO2015059690A1 (fr) 2013-10-24 2015-04-30 Yeda Research And Development Co. Ltd. Polynucléotides codant pour des polypeptides de système brex et leurs méthodes d'utilisation
US10584358B2 (en) 2013-10-30 2020-03-10 North Carolina State University Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
EP3066201B1 (fr) 2013-11-07 2018-03-07 Editas Medicine, Inc. Méthodes et compositions associées à crispr avec arng de régulation
US20150132263A1 (en) * 2013-11-11 2015-05-14 Radiant Genomics, Inc. Compositions and methods for targeted gene disruption in prokaryotes
AU2014362248A1 (en) 2013-12-12 2016-06-16 Massachusetts Institute Of Technology Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
EP4219699A1 (fr) 2013-12-12 2023-08-02 The Broad Institute, Inc. Ingénierie de systèmes, procédés et compositions de guide optimisées avec de nouvelles architectures pour la manipulation de séquence
EP3080271B1 (fr) 2013-12-12 2020-02-12 The Broad Institute, Inc. Systèmes, procédés et compositions pour manipulation de séquences avec systèmes crispr-cas fonctionnels optimisés
CA2932478A1 (fr) 2013-12-12 2015-06-18 Massachusetts Institute Of Technology Distribution, utilisation et applications therapeutiques des systemes crispr-cas et compositions pour l'edition du genome
WO2015089364A1 (fr) 2013-12-12 2015-06-18 The Broad Institute Inc. Structure cristalline d'un système crispr-cas, et ses utilisations
KR20160089530A (ko) 2013-12-12 2016-07-27 더 브로드 인스티튜트, 인코퍼레이티드 Ｈｂｖ 및 바이러스 질병 및 질환을 위한 ｃｒｉｓｐｒ­ｃａｓ 시스템 및 조성물의 전달，용도 및 치료적 적용
US10787654B2 (en) 2014-01-24 2020-09-29 North Carolina State University Methods and compositions for sequence guiding Cas9 targeting
CN106460003A (zh) 2014-04-08 2017-02-22 北卡罗来纳州立大学 用于使用crispr相关基因rna引导阻遏转录的方法和组合物
WO2015159068A1 (fr) * 2014-04-14 2015-10-22 Nemesis Bioscience Ltd Thérapeutiques
CA2956224A1 (fr) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Proteines cas9 comprenant des inteines dependant de ligands
CN107429241B (zh) 2014-08-14 2025-10-24 百奥赛图(北京)医药科技股份有限公司 Dna敲入系统
EP3633032A3 (fr) 2014-08-28 2020-07-29 North Carolina State University Nouvelles protéines cas9 et éléments de guidage pour le ciblage de l'adn et l'édition du génome
EP3197269A1 (fr) 2014-09-26 2017-08-02 Purecircle Usa Inc. Marqueurs de polymorphisme mononucléotidique (snp) pour le stévia
CN107208070B (zh) 2014-11-26 2021-09-07 技术创新动力基金（以色列）有限合伙公司 细菌基因的靶向消除
EP3889260A1 (fr) 2014-12-12 2021-10-06 The Broad Institute, Inc. Arn guides protégés (pgrnas)
WO2016106236A1 (fr) * 2014-12-23 2016-06-30 The Broad Institute Inc. Système de ciblage d'arn
AU2015369725A1 (en) 2014-12-24 2017-06-29 Massachusetts Institute Of Technology CRISPR having or associated with destabilization domains
WO2016130600A2 (fr) 2015-02-09 2016-08-18 Duke University Compositions et procédés pour l'édition de l'épigénome
AU2016270649B2 (en) 2015-05-29 2022-04-21 North Carolina State University Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids
US11155823B2 (en) 2015-06-15 2021-10-26 North Carolina State University Methods and compositions for efficient delivery of nucleic acids and RNA-based antimicrobials
WO2016205759A1 (fr) 2015-06-18 2016-12-22 The Broad Institute Inc. Modification et optimisation de systèmes, de méthodes, d'enzymes et d'échafaudages guides d'orthologues de cas9 et variant pour la manipulation de séquences
EP3129393B1 (fr) 2015-06-18 2021-08-04 The Broad Institute Inc. Mutations d'enzyme crispr qui réduisent les effets non ciblés
GB201514510D0 (en) 2015-08-14 2015-09-30 Nemesis Bioscience Ltd Delivery vehicle
US11286480B2 (en) 2015-09-28 2022-03-29 North Carolina State University Methods and compositions for sequence specific antimicrobials
WO2017062855A1 (fr) * 2015-10-09 2017-04-13 Monsanto Technology Llc Nouvelles nucléases guidé par l'arn et leurs utilisations
EP3362571A4 (fr) * 2015-10-13 2019-07-10 Duke University Ingénierie génomique avec systèmes crispr de type i dans des cellules eucaryotes
AU2016342380B2 (en) 2015-10-23 2022-04-07 President And Fellows Of Harvard College Nucleobase editors and uses thereof
IL259100B2 (en) 2015-11-30 2023-09-01 Univ Duke Therapeutic targets for human dystrophin gene repair using gene editing and methods for use
BR112018011503A2 (pt) 2015-12-07 2018-12-04 Zymergen Inc promotores da corynebacterium glutamicum
US11208649B2 (en) 2015-12-07 2021-12-28 Zymergen Inc. HTP genomic engineering platform
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
WO2017112620A1 (fr) 2015-12-22 2017-06-29 North Carolina State University Méthodes et compositions pour l'administration d'agents antimicrobiens à base de crispr
WO2017147278A1 (fr) 2016-02-25 2017-08-31 The Children's Medical Center Corporation Commutateur de classe personnalisé de gènes d'immunoglobuline dans un lymphome et un hybridome par la technologie crispr/cas9
EP3219799A1 (fr) 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Expression sgrna crispr conditionnelle
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
GB201819504D0 (en) * 2016-05-01 2019-01-16 Neemo Inc Harnessing heterologous and endogenous crispr-cas machineries for efficient markerless genome editing in clostridium
GB2552861B (en) 2016-06-02 2019-05-15 Sigma Aldrich Co Llc Using programmable DNA binding proteins to enhance targeted genome modification
US10544411B2 (en) 2016-06-30 2020-01-28 Zymergen Inc. Methods for generating a glucose permease library and uses thereof
KR102345899B1 (ko) 2016-06-30 2021-12-31 지머젠 인코포레이티드 박테리아 헤모글로빈 라이브러리를 생성하는 방법 및 이의 용도
US12214056B2 (en) 2016-07-19 2025-02-04 Duke University Therapeutic applications of CPF1-based genome editing
IL308426B1 (en) 2016-08-03 2025-11-01 Harvard College Adenosine nucleobase editors and uses thereof
JP7201153B2 (ja) 2016-08-09 2023-01-10 プレジデント アンド フェローズ オブ ハーバード カレッジ プログラム可能ｃａｓ９－リコンビナーゼ融合タンパク質およびその使用
WO2018039438A1 (fr) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation d'acides aminés non naturels dans des protéines au moyen de l'édition de bases
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
CA3057192A1 (fr) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Editeurs de nucleobase comprenant des proteines de liaison a l'adn programmable par acides nucleiques
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
EP3645716A2 (fr) 2017-06-25 2020-05-06 Snipr Technologies Limited Modification de populations microbiennes et modification de microbiote
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
KR20200121782A (ko) 2017-10-16 2020-10-26 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
US20190160120A1 (en) * 2017-11-29 2019-05-30 Snipr Biome Aps Dna, methods etc
WO2019118949A1 (fr) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systèmes et procédés de prédiction des résultats de la réparation en ingénierie génétique
EP3797160A1 (fr) 2018-05-23 2021-03-31 The Broad Institute Inc. Éditeurs de bases et leurs utilisations
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
WO2020072248A1 (fr) 2018-10-01 2020-04-09 North Carolina State University Système crispr-cas de type i recombinant
US12264330B2 (en) 2018-10-01 2025-04-01 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for killing target cells
WO2020072253A1 (fr) 2018-10-01 2020-04-09 North Carolina State University Système crispr-cas de type i recombinant et ses utilisations pour le criblage de cellules variantes
US12264313B2 (en) 2018-10-01 2025-04-01 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for genome modification and alteration of expression
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
WO2020092453A1 (fr) 2018-10-29 2020-05-07 The Broad Institute, Inc. Éditeurs de nucléobases comprenant geocas9 et utilisations associées
WO2020154500A1 (fr) 2019-01-23 2020-07-30 The Broad Institute, Inc. Protéines chargées supernégativement et utilisations associées
DE112020001342T5 (de) 2019-03-19 2022-01-13 President and Fellows of Harvard College Verfahren und Zusammensetzungen zum Editing von Nukleotidsequenzen
WO2020214842A1 (fr) 2019-04-17 2020-10-22 The Broad Institute, Inc. Éditeurs de base d'adénine présentant des effets hors cible réduits
EP4061153A4 (fr) * 2019-06-06 2023-05-10 Tata Consultancy Services Limited Système et méthode de lutte contre les infections par mycobacterium tuberculosis
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
US11859172B2 (en) 2020-01-02 2024-01-02 The Trustees Of Columbia University In The City Of New York Programmable and portable CRISPR-Cas transcriptional activation in bacteria
EP4146804A1 (fr) 2020-05-08 2023-03-15 The Broad Institute Inc. Méthodes et compositions d'édition simultanée des deux brins d'une séquence nucléotidique double brin cible
JP2025524469A (ja) 2022-06-24 2025-07-30 チューン セラピューティクス インコーポレイテッド 標的を定めた遺伝子抑制を介して低密度リポタンパク質を低減するための組成物、系、及び方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060269998A1 (en) * 2005-04-15 2006-11-30 North Carolina State University Methods and compositions to modulate adhesion and stress tolerance in bacteria
US7208317B2 (en) * 2002-05-02 2007-04-24 The University Of North Carolina At Chapel Hill In Vitro mutagenesis, phenotyping, and gene mapping
US20080124725A1 (en) * 2006-05-19 2008-05-29 Rodolphe Barrangou Tagged microorganisms and methods of tagging

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208317B2 (en) * 2002-05-02 2007-04-24 The University Of North Carolina At Chapel Hill In Vitro mutagenesis, phenotyping, and gene mapping
US20060269998A1 (en) * 2005-04-15 2006-11-30 North Carolina State University Methods and compositions to modulate adhesion and stress tolerance in bacteria
US20080124725A1 (en) * 2006-05-19 2008-05-29 Rodolphe Barrangou Tagged microorganisms and methods of tagging

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BROUNS ET AL.: "Small CRISPR RNAs Guide Antiviral Defense in Prokaryotes", SCIENCE, vol. 321, no. 5891, 15 August 2008 (2008-08-15), pages 960 - 964 *
HALE ET AL.: "Prokaryotic silencing (psi)RNAs in Pyrococcus furiosus.", RNA, vol. 14, no. 12, 2008, pages 2572 - 2579 *
HESPELL ET AL.: "Carbohydrate Metabolism in Spirochaeta stenostrepta", J. BACTERIOL., vol. 103, no. 1, 1970, pages 216 - 226 *
SANDERS: "Rapid escalation characterizes arms race between virus and host", UC NEWSROOM, 22 May 2008 (2008-05-22), BERKELEY, pages 1 - 3, Retrieved from the Internet <URL:httpl/www.universityofcalifornia.edu/news/article/17925> [retrieved on 20100623] *
SHAW ET AL.: "Metabolic engineering of a thermophilic bacterium to produce ethanol at high yield", PROC. NATL. ACAD. SCI. U S A, vol. 105, no. 37, September 2008 (2008-09-01), pages 13769 - 13774 *
TANNLER ET AL.: "'Screening of Bacillus subtilis transposon mutants with altered riboflavin production", METAB. ENG., vol. 10, no. 5, September 2008 (2008-09-01), pages 216 - 226 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400110B2 (en) 2015-05-06 2022-08-02 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US12514867B2 (en) 2015-05-06 2026-01-06 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US12226430B2 (en) 2015-05-06 2025-02-18 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11844760B2 (en) 2015-05-06 2023-12-19 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11642363B2 (en) 2015-05-06 2023-05-09 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11147830B2 (en) 2015-05-06 2021-10-19 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11547716B2 (en) 2015-05-06 2023-01-10 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11471531B2 (en) 2016-06-05 2022-10-18 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US10953090B2 (en) 2016-06-05 2021-03-23 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US10765740B2 (en) 2016-06-05 2020-09-08 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US12318445B2 (en) 2016-06-05 2025-06-03 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US11351252B2 (en) 2016-06-05 2022-06-07 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US11291723B2 (en) 2016-06-05 2022-04-05 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US11141481B2 (en) 2016-06-05 2021-10-12 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US11832598B2 (en) 2016-11-04 2023-12-05 Akeagen, Inc. Genetically modified non-human animals and methods for producing heavy chain-only antibodies
US10660316B2 (en) 2016-11-04 2020-05-26 Akeagen, Inc. Genetically modified non-human animals and methods for producing heavy chain-only antibodies
US11643653B2 (en) 2018-04-30 2023-05-09 Snipr Biome Aps Treating and preventing microbial infections
US11788085B2 (en) 2018-04-30 2023-10-17 Snipr Biome Aps Treating and preventing microbial infections
US11485973B2 (en) 2018-04-30 2022-11-01 Snipr Biome Aps Treating and preventing microbial infections
US10920222B2 (en) 2018-04-30 2021-02-16 Snipr Biome Aps Treating and preventing microbial infections
US12448619B2 (en) 2018-04-30 2025-10-21 Snipr Biome Aps Treating and preventing microbial infections
US11421227B2 (en) 2018-04-30 2022-08-23 Snipr Biome Aps Treating and preventing microbial infections
US12076375B2 (en) 2022-06-29 2024-09-03 Snipr Biome Aps Treating and preventing E coli infections

Also Published As

Publication number Publication date
WO2010075424A2 (fr) 2010-07-01

Similar Documents

Publication Publication Date Title
WO2010075424A3 (fr) Compositions et procédés de réduction de gènes procaryotes
WO2012164565A8 (fr) Compositions et procédés pour la régulation à la baisse de gènes procaryotes
WO2013032850A3 (fr) Compositions et procédés pour un assemblage haute-fidélité d&#39;acides nucléiques
WO2010127304A3 (fr) Procédés de séquençage
WO2014039692A3 (fr) Loci de performance fad2 et protéines se liant à un site spécifique cible correspondantes pouvant induire des cassures ciblées
WO2008058282A3 (fr) Procédés et compositions pour analyse à grande échelle d&#39;acides nucléiques par suppressions d&#39;adn
WO2008093847A1 (fr) Adn codant pour la xylitol déshydrogénase
WO2010062480A3 (fr) Procédés et compositions pour la production d&#39;alcools gras
WO2008052101A3 (fr) Ingénierie génomique automatisée à multiplexage
WO2011082425A3 (fr) Variants d&#39;alpha-amylase et polynucleotides les codant
WO2007124285A3 (fr) Polypeptides ayant une activité de glucoamylase et polynucléotides codant pour ceux-ci
NZ601247A (en) Targeted genomic alteration
MX342195B (es) Nucleótidos de terminación de rápida fotodescomposición 5-metoxi, 3&#39; -oh no bloqueados y métodos para secuenciación de ácido nucleico.
WO2008045460A3 (fr) Séquences de micro-arn de maïs
WO2010115016A3 (fr) Compositions constituées d&#39;une préparation d&#39;acides nucléiques et procédés associés
WO2010048337A3 (fr) Préservation d&#39;informations liées à une méthylation d&#39;adn génomique
WO2010027497A3 (fr) Préparations, compositions et procédés de séquençage d&#39;acides nucléiques
EP3358014A3 (fr) Procédé de stabilisation d&#39;acides nucléiques fonctionnels
WO2006005074A3 (fr) Nouvelle amplification d&#39;acides nucleiques par demarrage a chaud
WO2010042664A3 (fr) Procede et compositions pour produire des aldehydes gras
NZ597299A (en) Use of a cas gene in combination with CRISPR repeats for modulating resistance in a cell
WO2014162307A3 (fr) Procédés et appareil utilisables en vue de la synthèse d&#39;acides nucléiques
WO2011061032A3 (fr) Cellules, acides nucléiques, enzymes et leur utilisation, ainsi que procédé de production de sophorolipides
WO2009060124A3 (fr) Utilisation d&#39;oligonucléotides avec des bases modifiées dans l&#39;hybridation d&#39;acides nucléiques
WO2009089593A8 (fr) Procédé de préparation de produits nutritionnels, thérapeutiques ou organoleptiques à partir de glycérol brut

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09835782

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09835782

Country of ref document: EP

Kind code of ref document: A2